Tickborne rickettsioses are zoonoses caused by spotted fever group (SFG) *Rickettsia* spp. ([@R1]). The first human infection with *R. sibirica mongolitimonae* was reported in France in 1996 ([@R2]). This patient had rope-like lymphangitis from the eschar to the draining lymph node, and *R. sibirica mongolitimonae* infection was thus named lymphangitis-associated rickettsiosis ([@R3],[@R4]). Since then, other cases with or without rope-like lymphangitis have been described ([@R5]). Several SFG rickettsioses that have been considered nonpathogenic for decades are now associated with human infections, making these diseases useful as a paradigm for understanding emerging and reemerging infections ([@R6]). To further characterize human infections caused by *R. sibirica mongolitimonae*, we tested skin biopsy and swab samples and analyzed the clinical, epidemiologic, and diagnostic characteristics of patients with a rickettsiosis.

The Study
=========

During 2010--2014, we tested skin biopsy ([@R7]) and cutaneous swab samples from rickettsiosis inpatients and outpatients throughout France. These samples were received frozen or in transport media; when possible, serum samples were also collected and sent at room temperature. For patients with positive *Rickettsia* results, epidemiologic and clinical data were collected.

We extracted total genomic DNA from samples by using a QIAamp tissue kit (QIAGEN, Hilden, Germany). We screened samples for *Rickettsia* spp. by using a quantitative PCR assay selective for a 109-bp fragment of a hypothetical protein ([@R8]). For positive samples, PCR amplification and sequencing selective for the *glt*A and *omp*A genes were performed ([@R8]). Samples were cultured in human embryonic lung fibroblasts ([@R9]). All serum samples were tested by immunofluorescence assay for SFG rickettsial antigens and typhus group rickettsiae ([@R10]). Student *t* or χ^2^ tests were performed by using Epi Info version 6.0 software (Centers for Disease Control and Prevention, Atlanta, GA, USA). Means were compared by using analysis of variance or the Kruskal-Wallis test, on the basis of results of the Bartlett test for inequality of population variances. Proportions were compared by using the Mantel-Haenszel χ^2^ or Fisher exact tests when the expected value of a cell was \<0.05. *R. sibirica mongolitimonae* seasonality was assessed by using the autocorrelation module of PASW software version 17.02 (<http://www.spss.com.hk/statistics/>). p \<0.05 was considered significant.

We classified patients as definitively having a rickettsiosis if direct evidence of rickettsial infection was found on culture or molecular assays. Of 465 patients examined, 91 (20%) were infected with *Rickettsia* spp., most commonly *R. africae* (n = 36, 40%), followed by *R. conorii* (n = 21, 23%), *R. sibirica mongolitimonae* (n = 20, 22%), and *R. slovaca* (n = 14, 15%). Two cases of *R. sibirica mongolitimonae* infection in France have been reported ([@R11],[@R12]).

For patients infected with *R. sibirica mongolitimonae*, median age ± SD (interquartile range) was 43 ± 21 (2--70) years, and most (12, 60%) were male ([Technical Appendix](#SD1){ref-type="local-data"}Table 1). The most common *Rickettsia* species in France was *R. sibirica mongolitimonae.* Only 1 patient mentioned recent travel to Spain; all others denied recent travel. Five patients mentioned recent outdoor activities, 8 mentioned frequent contact with dogs, and 1 mentioned contact with horses. A tick bite or tick handling was reported by 6 patients. An autocorrelation analysis revealed significant seasonality for *R. sibirica mongolitimonae* cases (p\<0.001). Significantly more cases occurred during spring (April--June) (11 cases, 55%; p = 0.006), followed by summer (July--September) (8 cases, 40%, p = 0.01). One case occurred in October and none in winter.

The symptoms at disease onset included fever for all patients (duration 4--14 days), myalgia (n = 11, 55%), and headache (n = 3, 15%). Generalized maculopapular rash and an inoculation eschar developed in all patients. One patient had 3 eschars (buttocks, right hand, breast). A rope-like lymphangitis from the eschar to the draining lymph node was detected in 7 (35%) patients. One patient was admitted to an intensive care unit. For all 5 patients for whom an initial laboratory examination was available, increased liver enzymes (alanine aminotransferase, aspartate aminotransferase) and thrombocytopenia were found; 2 patients had hypoproteinemia. Oral doxycycline (7--14 days) was given to 19 patients; pristinamycin (7 days) was given to 1 patient. All outcomes were successful.

An eschar swab sample was available for 13 patients ([@R13]), and a skin biopsy sample was available for 10; all samples were positive for *R. sibirica mongolitimonae*. An acute-phase serum sample was also available for 13 patients; results of serologic testing were positive for only 2 (15%). A convalescent-phase serum sample was available from 5 patients; results were positive for 4 (80%). A skin biopsy sample was also positive for *R. sibirica mongolitimonae* by culture.

Statistical comparison of the 4 rickettsioses ([Table](#T1){ref-type="table"}) showed that a recent travel history was more common among patients with *R. africae* infection (p\<0.001). *R. slovaca* infection was associated with absence of fever or rash (p\<0.001 for each). Multiple eschars were associated with *R. africae* infection (p\<0.001). An eschar on the neck was a characteristic of infection with *R. sibirica mongolitimonae* (p = 0.002); on the scalp, *R. slovaca* (p\<0.001); on the trunk, *R. conorii* (p = 0.05); and on the lower limbs, *R. africae* (p\<0.001). For patients with rope-like lymphangitis, the probability of *R. sibirica mongolitimonae* infection was 100% (p\<0.001). Cervical lymphadenitis was associated with *R. slovaca* (p\<0.001), inguinal lymphadenitis with *R. africae* (p\<0.001), and axillary lymphadenitis with *R. sibirica mongolitimonae* infection (p = 0.01).

###### Epidemiologic and clinical characteristics of the main spotted fever group rickettsioses identified at the Unité de Recherche sur les Maladies Infectieuses et Tropicales Émergentes, Marseilles, France, 2010--2014\*

  Characteristic             *Rickettsia africae*        *R. conorii*                                       *R. slovaca*      *R. sibirica mongolitimonae*
  -------------------------- --------------------------- -------------------------------------------------- ----------------- ------------------------------
  No. cases                  36                          21                                                 14                20
  Geographic location        Zimbabwe and South Africa   Algeria, France, Morocco, Portugal, South Africa   France            France, Spain
  Median age ± SD (IQR), y   58 ± 12 (31--80)            53 ± 18 (10--80)                                   36 ± 23 (6--65)   43 ± 21 (2--70)
  Female sex                 14 (39)                     7 (33)                                             9 (64)            8 (40)
  Recent travel              36                          17                                                 0                 1
  Clinical signs                                                                                                              
  Fever                      35 (97)                     21 (100)                                           5 (36)            20 (100)
  Rash                       24 (67)                     20 (95)                                            3 (21)            19 (95)
  Enlarged lymph nodes       15 (42)                     3 (14)                                             14 (100)          12 (60)
  Lymphadenopathy location                                                                                                    
  Cervical                   1 (3)                       3 (14)                                             14 (100)          5 (25)
  Inguinal                   14 (39)                     0                                                  0                 3 (15)
  Axillary                   0                           0                                                  0                 4 (20)
  Eschar                     36 (100)                    18 (86)                                            14 (100)          20 (100)
  Multiple eschars           13 (36)                     0                                                  0                 3 (15)
  Eschar location                                                                                                             
  Scalp                      0                           2 (10)                                             14 (100)          0
  Lower limbs                32 (89)                     3 (14)                                             0                 7 (33)
  Upper limbs                2 (6)                       2 (10)                                             0                 4 (20)
  Trunk                      2 (6)                       5 (24)                                             0                 3 (15)
  Neck                       0                           0                                                  0                 4 (20)
  Lymphangitis               0                           0                                                  0                 7 (35)
  Treatment (duration, d)                                                                                                     
  Doxycycline                34 (1--20)                  21 (7--21)                                         12 (1--7)         19 (7--14)
  Amoxicillin                2 (7)                       None                                               None              None
  Pristinamycin              None                        1 (7)                                              None              1 (7)
  Azithromycin               None                        None                                               2 (4)             None

\*Values are no. (%) patients unless otherwise indicated. IQR, interquartile range.

Conclusions  
=============

*R. sibirica mongolitimonae* is considered a rare pathogen; only 30 cases of infection with this organism have been reported in Europe and Africa ([Technical Appendix](#SD1){ref-type="local-data"}Table 2), of which 11 patients had lymphangitis, 27 inoculation eschars, and 18 a rash. In agreement with previous authors, we found that the most common signs of *R. sibirica mongolitimonae* infection were fever and rash. The addition of rope-like lymphangitis cases to those in the literature revealed that 17 (35%) of patients with *R. sibirica mongolitimonae* infection had this manifestation. Ramos et al. proposed that the term lymphangitis-associated rickettsiosis may be unwarranted for *R. sibirica mongolitimonae* infection because it is not found in all patients infected with this organism and because other rickettsioses produce lymphangitis ([@R14]). However, only *R. sibirica mongolitimonae* infection is associated with rope-like lymphangitis extending from the eschar to the draining lymph node; to our knowledge, only 1 case of mild, local, but not rope-like lymphangitis in a patient with *R. africae* infection has been described ([@R15]). In accordance with previous reports from France and Spain ([@R3],[@R14]), we found that *R. sibirica mongolitimonae* infection was seasonal and that most cases occurred in the spring and summer.

Our strategy for diagnosing *Rickettsia* spp. infection on the basis of skin biopsy and cutaneous swab samples modified our knowledge of the epidemiology of SFG rickettsioses in France. We provide evidence that *R. sibirica mongolitimonae* infection is a frequent rickettsiosis, probably more frequent than *R. conorii* infection, which for decades has been considered the most common *Rickettsia* species in France.

###### Technical Appendix

Epidemiologic, clinical, and microbiological characteristics associated Rickettsia sibirica mongolitimonae infection and reported cases, France, 2010­---2014.
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